Stock PLSE PULSE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
7.81 USD -1.01% Intraday chart for Pulse Biosciences, Inc. +4.83% -36.19%
May. 14 Pulse Biosciences Appoints Burke Barrett as President, CEO MT
May. 14 Pulse Biosciences, Inc Announces CEO Changes CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PULSE BIOSCIENCES CELLFX NANOSECOND PULSED FIELD ABLATION TECHNOLOGY TO BE FEATURED IN SEVERAL PRESENTATIONS AT THE HEART RHYTHM SOCIETY 2024 ANNUAL MEETING
AQ
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
BU
Pulse Biosciences Enhances Executive Leadership Team
BU
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
BU
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
BU
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
BU
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
BU
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
BU
Pulse Biosciences Announces Plans to Initiate a Rights Offering
BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
BU
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
BU
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY
AQ
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
BU
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
BU
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
BU
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
BU
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
BU
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.
  5. Press Releases
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW